Notícias

Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced investors.

In the most recent trading session, Novavax (NVAX) closed at $10.11, indicating a +1.1% shift from the previous trading day.

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's continued surge, and the one clue hiding in a quiet peer stock reveals exactly what kind of bet the market is actually making.

Legislative headlines, not company announcements, have been steering attention toward Novavax (NVAX). Bipartisan lawmakers recently introduced the Protecting Approved Care Act, and the proposal has weighed on several healthcare stocks, including this vaccine developer. Recent trading reflects that pressure. Novavax’s share price is down 3.75% over the last day and 9.42% over the past week. The 30-day share price return of 14.66% feeds into a stronger year-to-date gain of 29.45% and a more...

Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same time, bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices and administrative requirements. We’ll now examine how...

A number of stocks fell in the morning session after bipartisan lawmakers introduced the Protecting Approved Care Act, legislation aimed at reforming prior authorization and payment rules in Medicare Advantage plans.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

A number of stocks jumped in the morning session after Morningstar reported that challenging macroeconomic conditions across broader equity markets drove a rotation into healthcare, lifting the sector index by approximately 7% quarter-to-date to reach a 5% valuation premium.

In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi’s commercial rollout of NUVAXOVID, combination vaccine development and early

Novavax (NASDAQ:NVAX) outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healt

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.

Novavax reported that partners Sanofi and Takeda have secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026–2027 vaccination season across the U.S., European Union, Japan, and other major markets. These approvals allow Novavax to participate in the upcoming COVID-19 vaccination season primarily through royalties and milestones, while its partners shoulder the commercial execution and infrastructure burden. We'll now examine how Novavax’s...

Novavax (NVAX) drew fresh attention after announcing that partners secured approvals for an updated Nuvaxovid formulation targeting the SARS CoV 2 XFG variant for the 2026 to 2027 vaccination season. The news has arrived after a mixed period for Novavax’s stock. The share price is up 26.16% over the past 30 days and 29.87% year to date, yet down 15.59% over 90 days. The 1 year total shareholder return sits at 23.96%, while the 5 year total shareholder return reflects a steep 96.32% decline,...

Novavax stock has delivered a sharp 5 year decline alongside a recent rebound, and the broader valuation checks now point to a mixed picture rather than a clear bargain or clear overvaluation at the current price. The share price return over 5 years is down 96.3%, which signals that long term holders have absorbed very heavy losses despite the recent bounce. Future demand for Novavax products and the company’s ability to convert that demand into steady cash flow can support the equity story,...

Novavax said Sanofi and Takeda received clearances for an updated Nuvaxovid formulation for the 2026-2027 COVID season.

The XFG-adapted vaccine targets older and high-risk patients, with deliveries to pharmacies and clinics beginning immediately.

Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.

Novavax stock is garnering attention from options traders

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how therapeutics stocks fared in Q2, starting with Novavax (NASDAQ:NVAX).

Check out the companies making headlines this week:

NVAX stock surges amid biotech stock rally following Moderna and Merck cancer breakthrough.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 6.9% in the afternoon session after positive trial results from peers Moderna and Merck for their personalized cancer vaccine boosted sentiment across the vaccine sector.

BioNTech, a former pioneer of mRNA cancer vaccines, was part of a broad rally Wednesday. Leerink analysts don’t expect the momentum to last.

By Avinash P and Purvi Agarwal Aug 19 (Reuters) - The main U.S. stock indexes were on track to open higher on Wednesday after a tech-led selloff in the previous session as investors assessed fresh